TYPE 1 DIABETES - RAPID ACCESS TO INTERVENTION DEVELOPMENT (T1D-RAID) RELEASE DATE: August 26, 2003 NOTICE: NOT-DK-03-007 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (http://www.niddk.nih.gov) National Cancer Institute (NCI) (http://www.nci.nih.gov) The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in collaboration with the National Cancer Institute (NCI), invites requests for use of the resources of NCI's Rapid Access to Intervention Development (RAID) to foster development of new therapeutics for type 1 diabetes (T1D-RAID). T1D-RAID is a special mechanism to make available to academic investigators the necessary resources to move novel molecules and concepts from bench to bedside more rapidly and effectively. Services that would be available include for example: production, bulk supply, GMP manufacturing, formulation and toxicology. T1D-RAID will make available, on a competitive basis, the preclinical development contract resources of NCI's Developmental Therapeutics Program. T1D-RAID is not a grant program. The goal of T1D-RAID is the rapid movement of novel molecules and concepts from the laboratory to the clinic for proof-of-principle clinical trials, using NCI's contract research mechanisms. T1D-RAID will assist investigators who submit successful requests by providing any (or all) of the preclinical development steps that may be obstacles to clinical translation. Suitable agents for T1D- RAID will include small molecules, biologics or vaccines for the treatment or prevention of type 1 diabetes and its complications. There are two receipt dates for requests for T1D-RAID support per year, November 1 and April 1. Current requests must be received by Nov. 1, 2003, with all materials submitted directly to the office listed below; do not submit materials to the Center for Scientific Review. For information on process, procedure and review criteria of requests for T1D-RAID resources, visit http://www.niddk.nih.gov/fund/diabetesspecialfunds/T1D-RAID/. Inquiries are encouraged, and the opportunity to clarify issues or questions is welcome. Academic investigators may have collaborations with small-business partners and still qualify for T1D-RAID funding. Non-profit organizations other than universities may also submit T1D-RAID Requests. Please note that a maximum of two distinct requests for support per investigator can be submitted for each receipt date. INQUIRIES: Inquiries regarding this initiative maybe directed to: T1D-RAID Myrlene Staten, MD Senior Advisor, Diabetes Research Translation Division of Diabetes, Endocrinology, and Metabolic Diseases, NIDDK, NIH 6707 Democracy Boulevard Bethesda, MD 20852-5460 Tel: 301-402-7886; Fax: 301-480-3503 T1D-RAID@niddk.nih.gov
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |